|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 126.2 USD | +0.36% |
|
-0.29% | +15.75% |
| Apr. 15 | Zacks Adjusts Price Target on Merck & Company to $132 From $128 | MT |
| Apr. 11 | Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust | CI |
OncoImmune reported positive results from a late-stage study of a coronavirus therapeutic candidate. "Merck to Buy OncoImmune Amid Covid-19 Vaccine Development," at 6:59 a.m. ET incorrectly said that OncoImmune reported positive results from a late-stage study of a coronavirus vaccine candidate.
(END) Dow Jones Newswires
11-23-20 0822ET
| 1st Jan change | Capi. | |
|---|---|---|
| +15.75% | 320B | |
| +28.79% | 676B | |
| +23.88% | 559B | |
| -5.84% | 356B | |
| +4.32% | 286B | |
| +3.34% | 213B | |
| -0.15% | 207B | |
| -9.08% | 199B | |
| -10.00% | 147B | |
| -7.82% | 142B |
MERCK & CO., INC. 
